Please login to the form below

Not currently logged in
Email:
Password:

Mochida and Wyeth in novel vanilloid pain tie-up

Mochida licenses a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists for use as a potential novel treatment for pain to Wyeth Pharmaceuticals

Mochida Pharmaceutical has licensed a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists for use as a potential novel treatment for pain to Wyeth Pharmaceuticals.

Per the Agreement, Wyeth wins an exclusive worldwide license to develop, manufacture, use and sell pharmaceutical products containing Mochida's TRPV1 antagonists. Mochida will receive an upfront payment and potential development milestone payments, as well as royalties on sales by Wyeth.

Mochida retains an option to co-develop and co-market in Japan with Wyeth.

TRPV1 is a receptor and ion channel, which is stimulated by various stimuli including capsaicin, an ingredient derived from chilli peppers.

A number of other large pharmaceutical companies are also researching TRPV1 receptors for use in reducing nociception from inflammatory and neuropathic pain models in rats. In humans, drugs acting at TRPV1 receptors could potentially be used to treat neuropathic pain associated with multiple sclerosis, chemotherapy, or amputation, as well as pain associated with the inflammatory response of damaged tissue, such as in osteoarthritis. Existing painkillers sometimes cause gastrointestinal disorders or renal disorders, which limits their use.

14th January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics